WO2006072197A1 - Adjuvant plasmidique pour un traitement par ultrasons focalises a haute intensite et son utilisation - Google Patents
Adjuvant plasmidique pour un traitement par ultrasons focalises a haute intensite et son utilisation Download PDFInfo
- Publication number
- WO2006072197A1 WO2006072197A1 PCT/CN2005/001361 CN2005001361W WO2006072197A1 WO 2006072197 A1 WO2006072197 A1 WO 2006072197A1 CN 2005001361 W CN2005001361 W CN 2005001361W WO 2006072197 A1 WO2006072197 A1 WO 2006072197A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hifu
- adjuvant
- auxiliary agent
- nano
- particle diameter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
Definitions
- the present invention relates to the field of medicine and medical treatment, and more particularly to the field of ultrasonic therapy, and more particularly, the present invention relates to a HIFU therapeutic plasmid adjuvant capable of increasing tissue energy deposition in a target area during HIFU treatment and application. Background technique
- High-intensity focused ultrasound (HIFU) technology has been clinically recognized as a new approach to the treatment of tumors and other diseases. It focuses on ultrasound to form high-intensity, continuous ultrasound energy on the lesion, resulting in transient high-temperature effects (65 to 100 ° C), cavitation, mechanical and sonochemical effects, selectively causing coagulative necrosis of the lesion , the ability of the tumor to lose proliferation, infiltration and metastasis.
- HIFU High-intensity focused ultrasound
- Another object of the present invention is to provide a method for the energy deposition of a target region in the treatment of HIFU by the HIFU therapeutic plasmid adjuvant of the present invention.
- Still another object of the present invention is to provide a use of the HIFU therapeutic plasmid-based adjuvant of the present invention for enhancing the effect of HIFU in treating diseases.
- the substance which is an auxiliary agent for HIFU treatment in the present invention is preferably a nano-scale biocompatible solid selected from magnetic biomaterials such as superparamagnetic nanoparticles (SPIO), hydroxyapatite (HAP) and carbonic acid.
- SPIO superparamagnetic nanoparticles
- HAP hydroxyapatite
- Carbonic acid is more preferably hydroxyapatite
- the auxiliary agent has a particle diameter of from 1 to 500 nm, preferably from 1 to 200 nm, more preferably from 10 to 100 nm.
- auxiliary agent for example, a nano-sized biocompatible solid of a desired particle size, for example, a magnetic biomaterial such as superparamagnetic nanoparticles (SPIO), hydroxyapatite (HAP) And calcium carbonate, formulated with an aqueous medium at a concentration A suspension of 0.1-150 g/L.
- a mixing device such as an ultrasonic shaker to completely and uniformly disperse the nanoscale biocompatible solids in the aqueous suspension medium.
- nanoscale refers to a particle size of greater than 1 nm and less than 1000 nm.
- a preferred technical solution of the present invention provides a HIFU therapeutic plasmid-based auxiliary agent comprising a core composed of a film-forming material.
- a continuous phase composed of a discontinuous phase and an aqueous medium, wherein the discontinuous phase is uniformly dispersed in the continuous phase, and the discontinuous phase has a particle diameter of 10 to 1000 nm, preferably 10 to 500 nm, more preferably 10 to 200 nm;
- the film-forming material is contained in the auxiliary agent in an amount of 0.1 to 100 g/L, preferably 0.5 to 20 g/L, more preferably 0.5 to 10 g/L; and the core material is nano-scale biocompatible.
- SPIO superparamagnetic nanoparticles
- HAP hydroxyapatite
- calcium carbonate preferably hydroxyapatite
- the film-forming material includes a lipid such as 3-sn-phosphatidylcholine (lecithin), 1,2-dipalmitoyl-sn-glycero-3-phosphatidylglycerol Base-sodium salt, 1,2-distearoyl-sn-glycero-3-phosphatidylcholine, 1,2-dipalmitoyl-sn-glycero-3-phosphatidyl-sodium salt, 1, 2-dipalmitoyl-sn-glycero-3-phosphatidylcholine, phosphatidylserine, hydrogenated phosphatidylserine, cholesterol, glycolipids; sugars, including, for example, glucose, fructose, sucrose, starch, and their different chains Long degradation products; proteins, including, for example, albumin, globulin, fibrinogen, fibrin, hemoglobin, and degradation products of plant chain proteins of different chain lengths, and the like.
- lipid such as 3-sn-
- the aqueous medium is distilled water, physiological saline or a glucose solution.
- the concentration of the glucose solution can reach 50% (w/V), but the aqueous medium used for the HIFU treatment for diabetic patients cannot use a glucose solution in the aqueous medium.
- the auxiliary agent may further contain sodium carboxymethyl cellulose (CMC-Na) or/and glycerol (glycerol), etc., and the content of the CMC-Na in the auxiliary agent is 0.01. It is preferably from 10 to 10 g/L, more preferably from 0.05 to 0.6 g/L, still more preferably from 0.1 to 0.3 g/L.
- glycerol in the auxiliary agent is 5 to 100 g/L.
- Other preferred adjuvants may also contain potassium carboxymethylcellulose, sodium carboxyethylcellulose, potassium carboxyethylcellulose, sodium carboxypropylcellulose, potassium carboxypropylcellulose, and the like.
- the pH of the auxiliary agent is adjusted to 3.0 to 6.5, preferably to 5.0 to 6.0.
- Both inorganic or organic acids can be used to adjust the pH of the adjuvant, preferably using acetic acid to adjust the pH of the adjuvant.
- a substance having a specific affinity for the tumor tissue or the lesion site may be added to the adjuvant.
- tumor antibodies Such as tumor antibodies.
- the HIFU therapeutic plasmid-based adjuvant provided by the present invention preferably encapsulates nano-scale magnetic biomaterial, hydroxyapatite and/or calcium carbonate with a lipid (more preferably phospholipid), which enables the adjuvant to pass through the blood smoothly. It circulates and is quickly swallowed by tissues rich in reticuloendothelial cells in the human body. It can be deposited in human tissues in a large amount of time, which can significantly change the acoustic environment of human tissues, thereby significantly enhancing the absorption characteristics of human tissue. Increases the energy deposition of target tissue during HIFU treatment, which can significantly improve the efficiency of HIFU treatment of tumors.
- nano-scale biocompatible solids coated with the film of the present invention it can be prepared as follows -
- the mixed solution obtained in the above step (1) is placed in a sound vibrometer, and subjected to sound vibration for 2 to 3 minutes under the conditions of a power of 400 to 800 W to form a uniformly dispersed and stable suspension.
- the mixture is sonicated twice to form a more dispersed, more stable suspension.
- the preparation method of the HIFU therapeutic plasmid auxiliary agent provided by the invention only needs to prepare the biocompatible solid into nanometer-sized particles; the sonic vibration meter can realize the uniform dispersion of the discontinuous phase in the aqueous medium, and
- the invention solves the problem that the nano-sized particles are easy to aggregate and increase the particle size, the equipment investment is small, the operation is simple, the uniform dispersion effect is good, and the production cost is low.
- the invention also provides a method for increasing energy deposition in a target area during HIFU treatment, characterized in that the patient is injected with an effective dose of the HIFU of the present invention by intravenous rapid infusion or bolus injection 0 to 168 hours before HIFU treatment.
- an effective dose of the HIFU of the present invention by intravenous rapid infusion or bolus injection 0 to 168 hours before HIFU treatment.
- the effective dose will vary depending on factors such as tumor type, patient weight, tumor location, tumor volume, and the like. However, the physician or pharmacist has the ability to determine the appropriate amount of injection for different patients. For example, it may be selected within the range of 0.1 to 10 ml of adjuvant/kg body weight, preferably within the range of 0.1 to 5 ml of adjuvant/kg body weight, more preferably 0.5 to 5 ml/kg of body weight.
- the term "injury” as used herein refers to a substantial change in the physiological state of a tumor or normal tissue, usually referred to as coagulative necrosis of a tumor or normal tissue.
- the unit volume of target tissue is quantified by the energy efficiency factor (EEF) of the ultrasonic energy required for damage.
- EEF energy efficiency factor
- F / V (J/ mm 3 ), which is defined as the ultrasound energy required to damage a tumor or normal tissue per unit volume.
- P the total sound power (W) of the HIFU source
- t the total treatment time (s)
- V is the damage volume (mm 3 ).
- HAP purchased from Biomaterial Engineering Research Center of Sichuan University
- lecithin for injection purchased from Shanghai Chemical Reagent Co., Ltd.
- CMC-Na purchased from Shanghai Chemical Reagent
- the particle diameter of the auxiliary discontinuous phase prepared is 10 to 1000 nm, and is mainly concentrated in 100 to 500 nm.
- Nano-sized hydroxyapatite was purchased from the Biomaterials Engineering Research Center of Sichuan University. It is a white powder with a particle size of 10 ⁇ 200nm and a normal distribution. HAP was prepared into a milky white suspension with a concentration of 25 g/L and 50 g/L with 9% physiological saline, and shaken for 2 minutes by ultrasonic vibration at 600 W before use to completely disperse uniformly.
- Example 1 The combination of the auxiliaries prepared and the JC type HIFU tumor treatment system
- the administration group irradiated 24 hours after the injection was referred to as the first administration group, and the administration group irradiated 48 hours after the injection was referred to as the second administration group.
- the TC type HIFU tumor treatment system (produced by Chongqing Haifu (HIFU) Technology Co., Ltd.) was subjected to spot irradiation of rabbit livers of one control group and two administration groups, respectively.
- JC type HIFU tumor treatment system is mainly composed of adjustable power generator, B-super monitoring system, therapeutic probe, mechanical motion control system, treatment bed and acoustic coupling device.
- the treatment head has a diameter of 150mm, a focal length of 150mm, an acoustic focal length of 2.3 x 2.4x26mm, a working frequency of ⁇ , a circulating degassing water standard of 3ppm and a mean sound intensity of 5500W7cm 2 .
- the irradiation power was 220 W
- the frequency was 1.0 MHz
- the irradiation depth was 20 mm
- the irradiation time was 15 seconds.
- EEF energy efficiency factor
- the CZF-1 type HIFU therapy device consists of a power source, a treatment head and circulating water. See Chinese Invention Patent No. 01144259.X.
- the working parameters are as follows: frequency 9.85MHz, power 5W, focal length 4mm, treatment method using fixed-point irradiation.
- Each liver was irradiated in groups of 2 to 3, each group was 3 points, and the irradiation time was 10 seconds. The incision was sutured after surgery. After 24 hours, rabbits were sacrificed by rapidly injecting air 10 ml into the ear vein, and the focal volume of the formed coagulative necrosis was measured, and the energy efficiency factor (EEF) was calculated.
- EEF energy efficiency factor
- the rabbit liver can be seen in the target area after the end of focused ultrasound treatment to form a clear round-like gray-white coagulative necrosis with clear boundaries.
- the volume of the focal field formed by the different HAP dosage groups after focused ultrasound treatment was significantly increased compared with the corresponding saline group, and the required energy efficiency factor was significantly reduced.
- Very significant P ⁇ 0.001.
- the volume of the focal region formed increased significantly, and the required energy efficiency factor decreased significantly. The difference was significant (PO.001).
- Table 3 shows the comparison of the focal volume and energy efficiency factor ( ⁇ s) of the experimental groups with different HAP dosages. Dosage amount n V/mm 3 EEF
- HAP group 50mg/kg 30 153.1 ⁇ 41.8 0.24 ⁇ 0.05
- the control group (10 rats) was given physiological saline 2 ml/kg, and HIFU liver scan was performed 24 hours later. Preoperative animals were treated with 8% sodium sulfide in the right chest and abdomen, and a new 0.2 ml/kg intramuscular anesthesia was given to the JC-A HIFU treatment device.
- the nano-HAP group could form a larger coagulative necrosis than the control group (p ⁇ 0.05), and the energy-efficiency factor required for HIFU treatment was also significantly reduced, and 24 hours and 48 hours after administration.
- the formation of the focal region necrosis volume is the largest, and the required energy efficiency factor is also the smallest, suggesting that this may be the best time for HIFU treatment after HAP medication.
- the volume of necrotic lesions formed gradually decreases.
- the therapeutic effect of HIFU was better enhanced than before administration (p ⁇ 0.05).
- Table 4 Comparison between different time groups and control groups after treatment. Time after treatment n Average treatment time (s) Average focal volume (mm 3 ) Average EEF control group 16 15 546.67 7.39 ⁇ 4.99
- n is the actual number of irradiation points in the table.
- nano-level HAP can significantly enhance the in vitro therapeutic effect of HIFU, and HIFU treatment at 48 to 72 hours after administration can produce the best enhancement effect on HIFU treatment.
- the HIFU therapeutic plasmid adjuvant provided by the invention can significantly improve the acoustic environment of the target region, and can reduce the ultrasonic energy required for the damage of the target tissue (tumor/non-tumor tissue) per unit volume, so that it can be high under a certain power. Efficiently treat deep, bulky tumors without damaging normal tissue on the acoustic pathway.
- the use of the adjuvant of the present invention makes it possible to effectively perform HIFU treatment on liver tumor patients without removing the ribs on the patient's therapeutic acoustic channel.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05782127A EP1847275A4 (en) | 2005-01-10 | 2005-08-30 | PLASMIDIC ADJUVANT FOR HIGH INTENSITY FOCUSED ULTRASONIC TREATMENT AND USE THEREOF |
JP2007549779A JP2008526784A (ja) | 2005-01-10 | 2005-08-30 | 高密度焦点式超音波治療に対するプラスミド増強剤およびその使用 |
AU2005324270A AU2005324270B2 (en) | 2005-01-10 | 2005-08-30 | A high-intensity focused ultrasound plasmid adjuvant and its use |
US11/794,927 US20080260790A1 (en) | 2005-01-10 | 2005-08-30 | Plasmid Enhancement Agent for High Intensity Focused Ultrasound Treatment and Use Thereof |
CA002593632A CA2593632A1 (en) | 2005-01-10 | 2005-08-30 | Plasmid enhancement agent for high intensity focused ultrasound treatment and use thereof |
BRPI0518495-9A BRPI0518495A2 (pt) | 2005-01-10 | 2005-08-30 | adjuvante plasmÍdio para ultra-som focalizado de alta intensidade e seu uso |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510000344.3 | 2005-01-10 | ||
CN200510000344A CN100574810C (zh) | 2005-01-10 | 2005-01-10 | 一种高强度聚焦超声治疗用质粒类助剂及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006072197A1 true WO2006072197A1 (fr) | 2006-07-13 |
Family
ID=36647405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2005/001361 WO2006072197A1 (fr) | 2005-01-10 | 2005-08-30 | Adjuvant plasmidique pour un traitement par ultrasons focalises a haute intensite et son utilisation |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080260790A1 (zh) |
EP (1) | EP1847275A4 (zh) |
JP (1) | JP2008526784A (zh) |
KR (1) | KR20070091645A (zh) |
CN (1) | CN100574810C (zh) |
AU (1) | AU2005324270B2 (zh) |
BR (1) | BRPI0518495A2 (zh) |
CA (1) | CA2593632A1 (zh) |
RU (1) | RU2359701C2 (zh) |
WO (1) | WO2006072197A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100427142C (zh) * | 2005-01-10 | 2008-10-22 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用助剂及其筛选方法 |
CN100431581C (zh) * | 2006-01-20 | 2008-11-12 | 丽珠医药集团股份有限公司 | 治疗禽流感的中药组合物、制备方法及其用途 |
WO2013059358A2 (en) | 2011-10-17 | 2013-04-25 | Butterfly Network, Inc. | Transmissive imaging and related apparatus and methods |
US9667889B2 (en) | 2013-04-03 | 2017-05-30 | Butterfly Network, Inc. | Portable electronic devices with integrated imaging capabilities |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767610A (en) * | 1984-10-19 | 1988-08-30 | The Regents Of The University Of California | Method for detecting abnormal cell masses in animals |
US5344640A (en) * | 1991-10-22 | 1994-09-06 | Mallinckrodt Medical, Inc. | Preparation of apatite particles for medical diagnostic imaging |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6165932A (ja) * | 1984-09-05 | 1986-04-04 | Bridgestone Corp | 防振装置 |
US5320906A (en) * | 1986-12-15 | 1994-06-14 | Vestar, Inc. | Delivery vehicles with amphiphile-associated active ingredient |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US6551576B1 (en) * | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US6613306B1 (en) * | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
DE19716732C2 (de) * | 1997-03-07 | 1999-03-25 | Max Delbrueck Centrum | Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung |
US7686763B2 (en) * | 1998-09-18 | 2010-03-30 | University Of Washington | Use of contrast agents to increase the effectiveness of high intensity focused ultrasound therapy |
CN100427142C (zh) * | 2005-01-10 | 2008-10-22 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用助剂及其筛选方法 |
-
2005
- 2005-01-10 CN CN200510000344A patent/CN100574810C/zh active Active
- 2005-08-30 CA CA002593632A patent/CA2593632A1/en not_active Abandoned
- 2005-08-30 JP JP2007549779A patent/JP2008526784A/ja active Pending
- 2005-08-30 KR KR1020077015584A patent/KR20070091645A/ko not_active Application Discontinuation
- 2005-08-30 WO PCT/CN2005/001361 patent/WO2006072197A1/zh active Application Filing
- 2005-08-30 US US11/794,927 patent/US20080260790A1/en not_active Abandoned
- 2005-08-30 EP EP05782127A patent/EP1847275A4/en not_active Withdrawn
- 2005-08-30 RU RU2007127665/14A patent/RU2359701C2/ru not_active IP Right Cessation
- 2005-08-30 BR BRPI0518495-9A patent/BRPI0518495A2/pt not_active IP Right Cessation
- 2005-08-30 AU AU2005324270A patent/AU2005324270B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767610A (en) * | 1984-10-19 | 1988-08-30 | The Regents Of The University Of California | Method for detecting abnormal cell masses in animals |
US5344640A (en) * | 1991-10-22 | 1994-09-06 | Mallinckrodt Medical, Inc. | Preparation of apatite particles for medical diagnostic imaging |
Non-Patent Citations (1)
Title |
---|
See also references of EP1847275A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU2005324270A1 (en) | 2006-07-13 |
EP1847275A4 (en) | 2008-04-23 |
RU2007127665A (ru) | 2009-01-27 |
AU2005324270B2 (en) | 2008-08-07 |
US20080260790A1 (en) | 2008-10-23 |
CN100574810C (zh) | 2009-12-30 |
CA2593632A1 (en) | 2006-07-13 |
CN1803197A (zh) | 2006-07-19 |
KR20070091645A (ko) | 2007-09-11 |
EP1847275A1 (en) | 2007-10-24 |
BRPI0518495A2 (pt) | 2008-11-25 |
JP2008526784A (ja) | 2008-07-24 |
RU2359701C2 (ru) | 2009-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Injectable and responsively degradable hydrogel for personalized photothermal therapy | |
Xu et al. | Magnetic hyperthermia ablation of tumors using injectable Fe3O4/calcium phosphate cement | |
WO2006072198A1 (fr) | Adjuvant pour un traitement par ultrasons focalises a haute intensite et son procede de depistage | |
KR20100029207A (ko) | 혈액 혈소판을 사용한 마이크로입자 및 나노입자의 전달 | |
Zhou et al. | Folate-targeted perfluorohexane nanoparticles carrying bismuth sulfide for use in US/CT dual-mode imaging and synergistic high-intensity focused ultrasound ablation of cervical cancer | |
WO2006072200A1 (fr) | Adjuvant d’emulsions au fluorocarbure pour un traitement hifu et utilisation de celui-ci | |
WO2006072201A1 (fr) | Adjuvant sous forme de particules pour un traitement hifu et son utilisation | |
WO2006072197A1 (fr) | Adjuvant plasmidique pour un traitement par ultrasons focalises a haute intensite et son utilisation | |
CN110575551B (zh) | 一种超声造影剂及其制备方法 | |
WO2017001686A1 (en) | Polymeric nanoparticles for enhancing hifu-induced ablation | |
KR20120077931A (ko) | 엠알유도 고강도집속초음파 치료 및 진단용 인지질 나노입자 및 이의 제조방법 | |
Sari et al. | Application of Stichopus hermanni Nanoparticle Gel in the Healing of Traumatic Ulcers | |
CN105641704B (zh) | 一种产泡聚乳酸羟基乙酸泡腾药物及制备方法和应用 | |
JP4585967B2 (ja) | 誘電加熱による癌治療法に使用する補助剤 | |
CN113413468B (zh) | 一种光热-硬化联合治疗的靶向纳米药物递送系统 | |
Liu et al. | Combination of high-intensity focused ultrasound irradiation and hydroxyapatite nanoparticle injection to injure normal goat liver tissue in vivo without costal bone incision |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020077015584 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007549779 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005324270 Country of ref document: AU Ref document number: 2593632 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007127665 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2005324270 Country of ref document: AU Date of ref document: 20050830 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005324270 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005782127 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005782127 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11794927 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0518495 Country of ref document: BR |